Please upgrade your browser.
T-Cell Receptor Gene-Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy
Adoptive therapy with genetically engineered T cells carrying redirected antigen specificity is a new option for the treatment of cancer. This approach is not yet available for metastatic renal cell carcinoma (RCC), due to the scarcity of therapeutically useful reagents. We analyzed tumor-infiltrating lymphocytes (TIL) from RCC to identify T-cell specificities with shared tumor-specific recognition to develop T-cell receptor (TCR)-engineered T lymphocytes for adoptive therapy of RCC.
To evaluate the efficacy and toxicity of the combination of bevacizumab, an angiogenesis inhibitor, and everolimus, an mTOR inhibitor, in the treatment of patients with advanced clear cell renal carcinoma.
Alpha Tau Omega, with the help of Twiin Productions, hosted the event at the East Beach Volleyball Courts in downtown Santa Barbara. Approximately 4,000 people attended the tournament, which featured music, food, a beer garden and plenty of volleyball. All proceeds from ticket sales were donated to the Kidney Cancer Association.
Learn why this social network is better than others for families dealing with renal cancers.
Smile For Your Child: A Parent's Guide To Finding Positive Energy During Diagnosis, Treatment, & Life After
Katy, Texas, author Tracy R. Gray discusses her book, Smile For Your Child: A Parent's Guide To Finding Positive Energy During Diagnosis, Treatment, & Life After, in this thirty-minute interview with Bill Bro, of the Kidney Cancer Association. Gray's son is a survivor of Wilms Tumor, a pediatric malignancy.
07 May 2010, London. View the agenda or register here: http://www.kidneycancer.org/knowledge/learn/medical-education-programs.
Charles Chuck V. Carew worked well beyond retirement, not stopping until cancer made it physically impossible. In fact, the U.S. Postal Service worker and Air Force retiree stayed on the job until three months before his 76th birthday.
World experts in the treatment of kidney cancer will gather in London 06 May 2010 to discuss cutting-edge treatments with patients and their family members. Also on the expert panel, a barrister who handles patient appeals to NICE. Travel subsidies for the indigent living in Europe are available. See "Calendar of Events" at http://kidneycancer.org for details.
This informative all-day meeting gave over 40 nurses from across Wales the opportunity to learn more about kidney cancer and improve patient care and their understanding of the disease.
|Powered by NeonCRM|